Transfer and Assignment of Securities Subscription Agreement, dated September 9, 2024, between the Sponsor, Oaktree Acquisition Holdings III LS, L.P. and the Registrant
Exhibit 10.9
Oaktree Acquisition Corp. III Life Sciences
c/o Oaktree Capital Management, L.P.
333 South Grand Avenue, 28th Floor
Los Angeles, California 90071
September 9, 2024
Oaktree Acquisition Holdings III LS, L.P.
c/o Oaktree Capital Management, L.P.
333 South Grand Avenue, 28th Floor
Los Angeles, California 90071
Oaktree Acquisition Holdings III LS, LLC
c/o Oaktree Capital Management, L.P.
333 South Grand Avenue, 28th Floor
Los Angeles, California 90071
RE: Assignment under Securities Subscription Agreement and Transfer of Class B ordinary shares
Pursuant to this assignment agreement (this Assignment Agreement) and Section 6.6 of the securities subscription agreement dated July 15, 2024, by and between Oaktree Acquisition Holdings III LS, L.P. (the Assignor) and Oaktree Acquisition Corp. III Life Sciences (the Company) (the Securities Subscription Agreement), Assignor, the Company and Oaktree Acquisition Holdings III LS, LLC (the Assignee) hereby agree to assign to the Assignee the rights and obligations of the Assignor under the Securities Subscription Agreement. Except for the substitution of the Assignor by the Assignee as the counterparty to the Securities Subscription Agreement pursuant to this Assignment Agreement, the terms of the Securities Subscription Agreement remain unchanged and all terms shall henceforth apply to the Assignee and the Transferred Shares (as defined below) it holds as if it were a party to the Securities Subscription Agreement.
The Assignor hereby agrees to transfer to the Assignee 5,031,250 Class B ordinary shares, $0.0001 par value per share (the Transferred Shares), of which up to 656,250 are subject to surrender and cancellation by the Assignee pursuant to Section 3.1 of the Securities Subscription Agreement. The Assignee acknowledges that the Transferred Shares are subject to the restrictions and obligations set forth in the Securities Subscription Agreement, including, but not limited, to those described in Section 3, Section 4, Section 6.1 and Section 7 of the Securities Subscription Agreement. Further, the Assignee acknowledges and affirms Section 5 and Section 6.3 of the Securities Subscription Agreement and agrees to enter into an agreement substantially in the form of the letter agreement to be entered into between the Company and the other officers and directors of the Company in connection with the consummation of the Companys initial public offering.
The Assignee hereby reaffirms the representations and warranties included in Section 2.1 and Section 6.12 of the Securities Subscription Agreement, including, but not limited to, the representation and warranty that it is an accredited investor as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the Securities Act) and acknowledges the transfer contemplated hereby is being made in reliance on a private placement exemption to accredited investors within the meaning of Section 501(a) of Regulation D under the Securities Act or similar exemptions under federal and state law. The Assignee did not decide to enter into this Assignment Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502 of Regulation D under the Securities Act. The Company hereby also acknowledges and affirms Section 6.3 of the Securities Subscription Agreement and reaffirms the representations and warranties included in Section 2.2 and Section 6.12 of the Securities Subscription Agreement.
It is intended that, to the extent that the Assignor is treated as a partnership for U.S. federal income tax purposes, the Assignee shall be treated as a continuation of the Assignor under Section 708 of the Internal Revenue Code of 1986, as amended, and accordingly the transactions contemplated herein shall be disregarded for U.S. federal income tax purposes.
[Signature Page Follows]
2
IN WITNESS WHEREOF, the undersigned, intending to be legally bound hereby and the Securities Subscription Agreement, have caused this Assignment Agreement to be duly executed as of the day and year first above written.
THE COMPANY:
OAKTREE ACQUISITION CORP. III LIFE SCIENCES | ||
a Cayman Islands exempted company | ||
By: | /s/ Zaid Pardesi | |
Name: Zaid Pardesi | ||
Title: Chief Executive Officer |
THE ASSIGNEE: |
OAKTREE ACQUISITION HOLDINGS III LS, LLC |
a Cayman Islands limited liability company |
By: Oaktree Acquisition Holdings III LS GP, Ltd., its Managing Member |
By: Oaktree Capital Management, L.P., its Sole Director |
By: | /s/ Peter Boos | |
Name: Peter Boos | ||
Title: Vice President | ||
By: | /s/ Brian Price | |
Name: Brian Price | ||
Title: Managing Director |
Agreed and Acknowledged: |
THE ASSIGNOR: |
OAKTREE ACQUISITION HOLDINGS III LS, L.P. |
a Cayman Islands exempted limited partnership |
By: Oaktree Acquisition Holdings III LS GP, Ltd., its General Partner |
By: Oaktree Capital Management, L.P., its Sole Director |
By: | /s/ Peter Boos | |
Name: Peter Boos | ||
Title: Vice President | ||
By: | /s/ Brian Price | |
Name: Brian Price | ||
Title: Managing Director |
3